Understanding how CAR T cell therapy works in solid tumors
Response and resistance to chimeric antigen receptor T cell therapy in human solid tumors using spatial multi-omics
This study is looking at how well CAR T cell therapy works for people with solid tumors like pancreatic and prostate cancer, and it aims to find out what makes the treatment more or less effective by examining tissue samples from patients before and after therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10921797 on NIH RePORTER |
What this research studies
This research investigates the challenges faced by chimeric antigen receptor (CAR) T cells when treating solid tumors, such as pancreatic and prostate cancers. By using advanced spatial multi-omics technology, the study will analyze tissue samples from patients before and after CAR T cell therapy to identify factors that influence treatment response and resistance. The goal is to uncover specific interactions between CAR T cells, tumor cells, and immune cells that may affect the therapy's effectiveness. This research aims to improve CAR T cell therapy outcomes for patients with solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors, particularly those undergoing CAR T cell therapy for pancreatic or prostate cancer.
Not a fit: Patients with hematologic malignancies or those not receiving CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to enhanced CAR T cell therapies that are more effective for patients with solid tumors.
How similar studies have performed: While CAR T cell therapy has shown success in blood cancers, this approach to solid tumors is relatively novel and has not been extensively tested.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Rech, Andrew John — University of Pennsylvania
- Study coordinator: Rech, Andrew John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.